Evidence map›Paper›PMID 42667094›Full record

ArticleMolecular therapy. Nucleic acids2026

Long-read target enrichment sequencing for rAAV integration site analysis in engineered clones with targeted viral insertion.

Erica Coratella, Myriam Lemmens, Mevion Oertli, Yoann Gilbart, Kristian Davidsen, Lara Bontadelli, Rebecca Bohnert, Joyce Rigal, Jennifer Bian, Tara Alpert and 8 more

Abstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Erica CoratellaNovartis Biomedical Research, Basel, Switzerland.
Myriam LemmensNovartis Biomedical Research, Cambridge, MA, USA.
Mevion OertliNovartis Biomedical Research, Basel, Switzerland.
Yoann GilbartNovartis Biomedical Research, Basel, Switzerland.
Kristian DavidsenNovartis Biomedical Research, Cambridge, MA, USA.
Lara BontadelliNovartis Biomedical Research, Basel, Switzerland.
Rebecca BohnertNovartis Biomedical Research, Basel, Switzerland.
Joyce RigalNovartis Biomedical Research, Cambridge, MA, USA.
Jennifer BianNovartis Biomedical Research, Cambridge, MA, USA.
Tara AlpertNovartis Biomedical Research, San Diego, CA, USA.
Martin BeibelNovartis Biomedical Research, Basel, Switzerland.
Vera RudaNovartis Biomedical Research, Cambridge, MA, USA.
Megumi Onishi-SeebacherNovartis Biomedical Research, Basel, Switzerland.
Ulrike NaumannNovartis Biomedical Research, Basel, Switzerland.
Azeddine ElhajoujiNovartis Biomedical Research, Basel, Switzerland.
Alex OdermattDivision of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.
Eloise HudryNovartis Biomedical Research, Cambridge, MA, USA.
Silvana LibertiniNovartis Biomedical Research, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Integration site analysis (ISA) plays a critical role in the genotoxicity assessment of recombinant adeno-associated viruses (rAAVs); however, ISA is challenged by the low integration rate, frequent vector genome rearrangements and the absence of well-characterized controls. Here, we generated 34 MCF10A-derived clones harboring recombinant adeno-associated viruses (rAAV) insertions at CRISPR-Cas9-induced double-strand breaks as cellular reference material and used these cell lines to evaluate long-read target enrichment sequencing (LR-TES) for rAAV ISA. LR-TES findings were complemented by droplet digital PCR quantification of vector copy number, long-range PCR analysis of on-target integration, and whole-genome sequencing on selected clones. Dilution experiments established a limit of detection of 1% under the tested conditions. LR-TES enabled genome-wide identification of vector-host junctions and structural characterization of integrated vector genomes, detecting targeted and non-targeted insertions, genomic deletions, and extensive vector restructuring across the clone panel. Only ∼29% of the integrated vector payload remained intact, while the observed truncations, rearrangements, or concatemers highlighted the structural complexity that ISA must resolve in rAAV settings. Together, the engineered clonal controls and optimized LR-TES provide reference material and a technical framework supporting rAAV ISA in safety evaluation, particularly when high structural resolution and specificity are needed to interpret predominant integration events.

Indexed as

insertional mutagenesisintegration site analysislimit of detectionMT: Clinical ApplicationsrAAVstable clonestarget enrichment sequencing

Identifiers

PMID42667094
PMCPMC13524469

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.